MedPath
Found 48 clinical trials|View Analysis
Sort by:

Enfortumab Vedotin and Pembrolizumab Followed by Cystectomy And/or Ureterectomy for the Treatment of Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Phase 4
Not yet recruiting
Conditions
Locally Advanced Bladder Urothelial Carcinoma
Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
Stage III Bladder Cancer AJCC V8
Stage IV Bladder Cancer AJCC V8
Stage IV Renal Pelvis and Ureter Cancer AJCC V8
Interventions
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Cystectomy
Drug: Enfortumab Vedotin
Procedure: Local Therapy
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Other: Questionnaire Administration
Procedure: Ureterectomy
First Posted Date
2025-01-08
Last Posted Date
2025-01-08
Lead Sponsor
Mayo Clinic
Target Recruit Count
75
Registration Number
NCT06764095
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs

Not Applicable
Recruiting
Conditions
Oligometastatic Disease
Ureter Cancer
Renal Pelvic Carcinoma
Interventions
Drug: Systematic drug treatment
Radiation: Systematic therapy combined with radiotherapy
First Posted Date
2024-10-22
Last Posted Date
2024-10-22
Lead Sponsor
Not specified
Target Recruit Count
102
Registration Number
NCT06652022
Locations
🇨🇳

Departmeng of Urology, Peking University First Hospital, Beijing, China

🇨🇳

Department of Radiotherapy Oncology, Peking University First Hospital, Beijing, China

Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC

Recruiting
Conditions
Ureter Cancer
Renal Pelvic Carcinoma
Advanced Urothelial Carcinoma
Interventions
Other: surveillance alone
Combination Product: Immunotherapy+radiotherapy
First Posted Date
2024-09-19
Last Posted Date
2024-11-05
Lead Sponsor
Not specified
Target Recruit Count
60
Registration Number
NCT06598761
Locations
🇨🇳

Departmeng of Urology, Peking University First Hospital, Beijing, China

🇨🇳

Department of Radiotherapy Oncology, Peking University First Hospital, Beijing, China

Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria

Not yet recruiting
Conditions
Urothelial Carcinoma
Hematuria
Ureter Cancer
Renal Pelvis Cancer
Bladder Cancer
First Posted Date
2024-06-21
Last Posted Date
2024-07-05
Lead Sponsor
Changhai Hospital
Target Recruit Count
1200
Registration Number
NCT06469229
Locations
🇨🇳

Changhai Hospital, Shanghai, Shanghai, China

Urine DNA Methylation Detection for Hematuria Evaluation

Not yet recruiting
Conditions
Ureter Cancer
Urothelial Carcinoma
Bladder Cancer
Renal Pelvis Cancer
Hematuria
First Posted Date
2024-05-24
Last Posted Date
2024-06-20
Lead Sponsor
Changhai Hospital
Target Recruit Count
71
Registration Number
NCT06427993
Locations
🇨🇳

Changhai Hospital, Shanghai, Shanghai, China

Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery

Phase 3
Recruiting
Conditions
Ureter Cancer
Benign Renal Neoplasm
Calculus of Kidney and Ureter
Congenital Ureteric Anomaly
Other Specified Disorders of Kidney and Ureter
Ureteric Reflux
Benign Neoplasm of Ureter
Renal Cancer
Interventions
Drug: lidocaine infusion
Drug: spinal analgesia with morphine and bupivacaine
First Posted Date
2024-04-05
Last Posted Date
2024-05-03
Lead Sponsor
Hans Bahlmann
Target Recruit Count
220
Registration Number
NCT06349668
Locations
🇸🇪

University Hospital Linköping, Linköping, Sweden

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Phase 3
Active, not recruiting
Conditions
Metastatic Bladder Urothelial Carcinoma
Advanced Renal Pelvis Urothelial Carcinoma
Advanced Ureter Urothelial Carcinoma
Stage III Urethral Cancer AJCC v8
Metastatic Renal Pelvis Urothelial Carcinoma
Stage IV Renal Pelvis and Ureter Cancer AJCC v8
Stage IV Renal Pelvis Cancer AJCC v8
Stage IV Ureter Cancer AJCC v8
Stage IV Urethral Cancer AJCC v8
Advanced Bladder Urothelial Carcinoma
Interventions
Drug: Avelumab
Procedure: Biospecimen Collection
Procedure: Bone Scan
Drug: Cabozantinib S-malate
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2021-10-26
Last Posted Date
2024-12-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
654
Registration Number
NCT05092958
Locations
🇺🇸

Cancer Hematology Centers - Flint, Flint, Michigan, United States

🇺🇸

Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

🇺🇸

Sutter Auburn Faith Hospital, Auburn, California, United States

and more 273 locations

UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis.

Conditions
IMAGE
Cytology
Diagnoses Disease
Ureter Cancer
Urothelial Carcinoma
Interventions
Diagnostic Test: UroCAD assay, CTU examination and urine cytology
First Posted Date
2021-09-14
Last Posted Date
2021-09-14
Lead Sponsor
Changhai Hospital
Target Recruit Count
110
Registration Number
NCT05043662
Locations
🇨🇳

Changhai Hospital, Shanghai, Shanghai, China

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Phase 1
Recruiting
Conditions
Locally Advanced Bladder Urothelial Carcinoma
Locally Advanced Urethral Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Locally Advanced Renal Pelvis Urothelial Carcinoma
Locally Advanced Ureter Urothelial Carcinoma
Metastatic Renal Pelvis Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Stage IIIB Bladder Cancer AJCC v8
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Echocardiography
Drug: Enfortumab Vedotin
Drug: Erdafitinib
Procedure: Multigated Acquisition Scan
First Posted Date
2021-07-15
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
30
Registration Number
NCT04963153
Locations
🇺🇸

Los Angeles General Medical Center, Los Angeles, California, United States

🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

UCHealth University of Colorado Hospital, Aurora, Colorado, United States

and more 6 locations

Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression

Phase 2
Recruiting
Conditions
Locally Advanced Urothelial Carcinoma
Locally Advanced Ureter Urothelial Carcinoma
Metastatic Renal Pelvis Urothelial Carcinoma
Recurrent Renal Pelvis Urothelial Carcinoma
Recurrent Ureter Urothelial Carcinoma
Stage IIIA Bladder Cancer AJCC v8
Unresectable Ureter Urothelial Carcinoma
Unresectable Urethral Urothelial Carcinoma
Unresectable Urothelial Carcinoma
Locally Advanced Bladder Urothelial Carcinoma
Interventions
Other: Diagnostic Laboratory Biomarker Analysis
Biological: Nivolumab
Drug: Relatlimab
First Posted Date
2021-07-07
Last Posted Date
2024-02-08
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT04953104
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath